iXPress Genes was awarded a Phase II Department of Defense Small Business Innovation contract to develop extremophile-derived novel antibiotics to protect soldiers from biowarfare agents.
Learn more here.
iXPress Genes was awarded a Phase II Department of Defense Small Business Innovation contract to develop extremophile-derived novel antibiotics to protect soldiers from biowarfare agents.
Learn more here.